Hookipa Pharma Inc (NASDAQ:HOOK) Sees Large Drop in Short Interest

Hookipa Pharma Inc (NASDAQ:HOOK) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 315,900 shares, a drop of 5.2% from the March 15th total of 333,400 shares. Currently, 0.5% of the shares of the company are sold short. Based on an average daily volume of 562,100 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On Hookipa Pharma

A number of hedge funds have recently bought and sold shares of HOOK. Bank of America Corp DE lifted its position in shares of Hookipa Pharma by 1.2% in the first quarter. Bank of America Corp DE now owns 429,535 shares of the company’s stock valued at $316,000 after acquiring an additional 5,199 shares in the last quarter. State Street Corp lifted its stake in shares of Hookipa Pharma by 18.5% in the second quarter. State Street Corp now owns 169,174 shares of the company’s stock worth $149,000 after buying an additional 26,367 shares in the last quarter. Royal Bank of Canada boosted its position in Hookipa Pharma by 10.8% during the third quarter. Royal Bank of Canada now owns 290,956 shares of the company’s stock worth $390,000 after acquiring an additional 28,263 shares during the last quarter. Virtu Financial LLC purchased a new stake in Hookipa Pharma during the 2nd quarter valued at about $47,000. Finally, Mirabella Financial Services LLP purchased a new stake in Hookipa Pharma during the 1st quarter valued at about $82,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.

Hookipa Pharma Stock Performance

HOOK stock opened at $0.76 on Tuesday. Hookipa Pharma has a one year low of $0.41 and a one year high of $2.05. The firm’s fifty day moving average is $0.73 and its 200 day moving average is $0.64. The firm has a market cap of $75.20 million, a PE ratio of -0.86 and a beta of 1.02.

Hookipa Pharma (NASDAQ:HOOK) last posted its earnings results on Friday, March 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%. The business had revenue of $7.41 million for the quarter, compared to analyst estimates of $3.60 million. Research analysts predict that Hookipa Pharma will post -0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $6.50 price objective on shares of Hookipa Pharma in a research note on Monday, March 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $5.00 price target on shares of Hookipa Pharma in a research report on Monday, March 25th.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.